“GlaxoSmithKline has first option on commercialisation of ISIS antisense drugs.”
ANP’s partnership with ISIS for ALT1102/3 could see us at the negotiating table of GlaxoSmithKline for commercialisation.
ISIS is very cashed up right now with 470 million at call and i bet they will want a bigger share of ALT1103.... ANP could very well have all the funding they ever want with these upcoming results as they contain independently certified IGF-I reduction levels which is proof of concept PoC.
These drugs have an easy path to market no doubt about it GSK will see things move fast for ANP!
I think the big bang may be even closer than i first thought.... not hard to work out why the directors buying?!!
JMO and Good Luck!
antisense drugs pass and approved!!, page-18
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
-0.003(3.37%) |
Mkt cap ! $77.53M | |||
| Open | High | Low | Value | Volume |
| 8.9¢ | 8.9¢ | 8.5¢ | $584.3K | 6.750M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 379793 | 8.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |